Price
No data yet.
Social Signal Score
Revenue
$5.86MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jayson Rieger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 76
- Beta
- 1.50
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -13.14
Financials
Revenue
$5.86M-51.1%Net Income
$-13.15MEBITDA
$-12.97MFree Cash Flow
$-9.28MEPS (diluted)
$-0.62Shares Outstanding (diluted)
21.31M+729.1%Operating Expenses
$16.38MCash & Debt
$11.20MReturn of Capital
$0.00Revenue by Segment (annual)
$35.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $35.58M | $-17.89M | $-1.68 |
| 2024 | $7.57M | $-76.58M | $-14.78 |
| 2023 | $5.12M | $-67.00M | $-14.78 |
| 2022 | $9.03M | $-24.49M | $-7.17 |
| 2021 | $12.00M | $-35.08M | $-12.97 |
| 2020 | $0.00 | $-45.50M | $-17.08 |
| 2019 | $0.00 | $-28.21M | $-11.33 |
| 2018 | $0.00 | $-20.65M | $-8.31 |
| 2017 | $0.00 | $-4.46M | $-3.80 |
| 2016 | $0.00 | $-1.91M | $-0.74 |
Valuation
VRCAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences – Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
…topline data currently expected in mid-2027 – WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced completion of enrollment of the first pivotal clinical trial (COVE-2) of its global Phase 3 program evaluating YCANTH® (VP-102) for the treatment of common warts.
View source ↗
Earnings
Fri, Nov 13(in 2 months)
Consensus estimate $-0.50 per share
Typical surprise +19.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.62 vs $-0.39miss
- Tue, May 12$-0.41 vs $-0.59beat
- Wed, Mar 11$-0.51 vs $-0.43miss
- Fri, Nov 14$-0.03 vs $-1.14beat
- Tue, Aug 12$0.02 vs $-0.70beat
- Tue, May 13$-1.00 vs $-1.23beat
Estimates and results for VRCA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VRCA officers and directors.
- Bought
- $75.7m
- Sold
- $1.1m
30 trades
19 trades
- Rosenberg Noah L.bought
- Kirby John J.bought
- Zawitz Davidbought
- Rieger Jaysonbought
- Rosenberg Noah L.bought
- Rieger Jaysonbought
- Rosenberg Noah L.bought
- Rosenberg Noah L.bought
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VRCA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.